Stephen Lane

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

Joachim von Pawel, Joan H. Schiller, Frances A. Shepherd et al. · Journal of Clinical Oncology · 1999 · 960 citations

Medicine, Oncology, Pharmacology +12

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess et al. · The Lancet Oncology · 2018 · 658 citations · Full text

Medicine, Dermatology, Oncology +14

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Georgina V. Long, Keith T. Flaherty, Daniil Stroyakovskiy et al. · Annals of Oncology · 2017 · 652 citations · Full text

Medicine, Oncology, Pharmacology +17

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

Georgina V. Long, Jean‐Jacques Grob, Paul Nathan et al. · The Lancet Oncology · 2016 · 312 citations

Medicine, Oncology, Pharmacology +16

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

Joachim von Pawel, U. Gatzemeier, Jean-Louis Pujol et al. · Journal of Clinical Oncology · 2001 · 233 citations

Medicine, Oncology, Pharmacology +11